Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis
Currently, special attention is paid to timely treatment for active forms of multiple sclerosis (MS), especially for highly active MS (HAMS), in which there are ≥2 exacerbations and corresponding activity signs that are detected by magnetic resonance imaging (MRI) regardless of previous therapy with...
Saved in:
| Main Authors: | K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. V. Davydovskaya, M. N. Zakharova, N. A. Malkova, A. I. Nilov, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, F. A. Khabirov, M. V. Shumilina |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2020-06-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/1359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres
by: A. N. Boyko, et al.
Published: (2024-08-01) -
Clinical recommendations for the use of ocrelizumab in patients with multiple sclerosis
by: A. N. Boyko, et al.
Published: (2019-11-01) -
Cost-Consequences of Cladribine Tablets for the Treatment of Highly Active Relapsing–Remitting Multiple Sclerosis in Italy
by: Barbara Polistena, et al.
Published: (2025-06-01) -
Experience of cladribine tablets usage in the treatment of multiple sclerosis in the Multiple Sclerosis Centre of the Khanty-Mansi Autonomous Area — Yugra
by: A. A. Sokolova, et al.
Published: (2024-06-01) -
Assessment of the impact of reconstitution therapies—cladribine tablets and alemtuzumab—on the atrophy progression among patients with relapse-remitting multiple sclerosis
by: Aleksandra Pogoda-Wesołowska, et al.
Published: (2025-02-01)